Abstract
Ductal adenocarcinoma accounts for over 90 % of pancreatic malignancies. Other less common pancreatic tumors include neuroendocrine cancers, acinar cell carcinoma, pancreatoblastoma, squamous cell carcinoma, and occasional benign conditions. Rarely, the pancreas can be the site of metastases from other solid tumor malignancies (e.g., colon, breast, renal cancer) [1]. Pancreatic adenocarcinoma has a mortality rate virtually identical to that of its incidence with conventional cancer treatments having little impact on long-term survival. In Canada, about 3,800 new cases and about 3,700 deaths from pancreatic cancer occur annually. It is the fourth leading cause of cancer-related death in both males and females (4.6 % and 5.6 % of cancer-related deaths, respectively) [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
De Vita Jr VT, Lawrence T, Rosenberg SA. Cancer. Principles and practice of oncology. 8th ed. Vol. 1. Philadelphia, PA; 2008. p. 1118-1120.
Canadian Cancer Society/National Cancer Institute of Canada: Canadian cancer statistics 2007. Toronto, Canada. 2008; ISSN 0835-2976.
Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffae E, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001;61:4923–32.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46.
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.
Berger HG, Rau B, Gansauge F, et al. Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003;27:1075–84.
Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality and survival after the Whipple procedure. Ann Surg. 1987;206:358–65.
Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2001;5:681.
Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.
Verslype C, Van Cutsem E, Dicato M, et al. The management of pancreatic cancer. Current expert and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18 Suppl 7:vii1–10.
Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998;228:508–17.
Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemeos JP. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410–27.
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the pancreas. 201 patients. Ann Surg. 1995;22:721–33.
Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.
Klinkerbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer group. Ann Surg. 1999;230:776–82. discussion 782–784.
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.
Heinemann V, Boeck S. Perioperative management of pancreatic cancer. Ann Oncol. 2008;19 Suppl 7:vii273–8.
Crane CH, Ben-Losef E, Small Jr W. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350:2713–5. author reply 2713–1715.
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA. 2007;297:267–77.
Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicentre phase III of adjuvant chemotherapy and gemcitabine versus observation in patients with resected pancreatic cancer. ASCO Annual Meeting Proceedings. 2008;26(18S):LBA4504.
Rhodes JM. Usefulness of novel tumor markers. Ann Oncol. 1999;10 Suppl 4:S118–21.
Hermann R, Jelic S. Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii25–6.
NCCN clinical guidelines in oncology. Pancreatic Adenocarcinoma. Version 1.207. www.nccn.org.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Moore, M.J., Stathis, A. (2013). Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_26
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_26
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)